Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Launched by NEWAMSTERDAM PHARMA · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called obicetrapib, both on its own and combined with another medication called Repatha, on a specific type of cholesterol known as Lp(a) in patients who have high levels of it. Lp(a) can contribute to heart disease, so understanding how these treatments lower Lp(a) levels is important for managing dyslipidemias, which are conditions related to abnormal cholesterol levels.

To be eligible for this trial, patients should have an Lp(a) level greater than 50 mg/dL and LDL cholesterol (often referred to as "bad" cholesterol) above 70 mg/dL. Participants will take obicetrapib for 8 weeks, followed by a combination of obicetrapib and Repatha for another 8 weeks, with blood tests to measure their Lp(a) levels at the beginning and end of the study. The trial is open to both men and women aged between 65 and 74 years. It's important to note that individuals with certain health conditions, like very high blood sugar, or recent heart problems, may not qualify for this study. Overall, this trial aims to find better ways to manage cholesterol levels and improve heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Lp(a) \>50 mg/dL
• • LDL-C \>70 mg/dL
• • TG \< 400mg/dL
• Exclusion Criteria:
• • HbA1c\>=10 or FPG \>=270 mg/dL
• • CV events within 3 months of screen